These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 19417977)

  • 1. Successful treatment of chronic hepatitis C virus infection with peginterferon alpha-2a and ribavirin in patients with sickle cell disease.
    Ayyub MA; El-Moursy SA; Khazindar AM; Abbas FA
    Saudi Med J; 2009 May; 30(5):712-6. PubMed ID: 19417977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peg-interfon alpha-2a and low-dose ribavirin for treatment of hepatitis C virus infection in patients with sickle-cell anemia in Saudi Arabia.
    Agha A; Chakik R; Abdulhadi Ali MM; Alsaudi D; Sammito G; Giannini EG
    Ann Saudi Med; 2013; 33(6):610-3. PubMed ID: 24413867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
    Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
    N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C].
    Kim KT; Han SY; Kim JH; Yoon HA; Baek YH; Kim MJ; Lee SW; Jang JS; Lee JH; Roh MH
    Korean J Hepatol; 2008 Mar; 14(1):36-45. PubMed ID: 18367856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virological response of Tunisians patients treated by peginterferon plus ribavirin for chronic hepatitis C: a preliminary study.
    Belhadj N; Houissa F; Elloumi H; Ouakaa A; Gargouri D; Romani M; Kilani A; Kochlef A; Kharrat J; Ghorbel A
    Tunis Med; 2008 Apr; 86(4):341-5. PubMed ID: 19476135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Nakano S; Arakawa T
    Liver Int; 2009 Jan; 29(1):120-5. PubMed ID: 18384519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
    Yu ML; Lee CM; Chuang WL; Lu SN; Dai CY; Huang JF; Lin ZY; Hu TH; Chen CH; Hung CH; Wang JH; Chen CL; Kao JH; Lai MY; Liu CH; Su TH; Wu SS; Liao LY; Kuo HT; Chao YC; Tung SY; Yang SS; Chen PJ; Liu CJ; Chen DS
    J Infect Dis; 2010 Jul; 202(1):86-92. PubMed ID: 20482252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients.
    Reddy KR; Messinger D; Popescu M; Hadziyannis SJ
    J Viral Hepat; 2009 Oct; 16(10):724-31. PubMed ID: 19486469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
    Di Bisceglie AM; Ghalib RH; Hamzeh FM; Rustgi VK
    J Viral Hepat; 2007 Oct; 14(10):721-9. PubMed ID: 17875007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.
    von Wagner M; Hofmann WP; Teuber G; Berg T; Goeser T; Spengler U; Hinrichsen H; Weidenbach H; Gerken G; Manns M; Buggisch P; Herrmann E; Zeuzem S
    Hepatology; 2008 Nov; 48(5):1404-11. PubMed ID: 18846541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
    Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
    Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on peginterferon-alpha-2a (40 kD) plus ribavirin in the management of chronic hepatitis C mono-infection.
    Keam SJ; Cvetković RS
    BioDrugs; 2009; 23(1):63-8. PubMed ID: 19344193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in Japanese pediatric and young adult patients: a survey of the Japan Society of Pediatric Hepatology.
    Tajiri H; Inui A; Kiyohara Y; Suzuki M; Kagimoto S; Etani Y; Shimizu T; Fujisawa T
    Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1256-60. PubMed ID: 19474745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virological response at week 4.
    Sánchez-Tapias JM; Crespo J; Diago M; Pérez R; Romero-Gómez M; Muñoz-Sánchez M
    Methods Find Exp Clin Pharmacol; 2002 Nov; 24(9):579-84. PubMed ID: 12616704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.